Gara Jalqabaatti › Kansaar Onnee Triple-Negative › Minnesota › Rochester
Qorannoo klinikaalii Kansaar Onnee Triple-Negative Rochester, MN keessatti
Qorannoo 11 Kansaar Onnee Triple-Negative f Rochester fi naannoo isaa (kilomeetira 30 keessatti) hirmaatuu jiru. Qorannoo banaa eenyu akka hirmaatu fi akkamitti garee qorannoo akka quunnaman ilaali.
Takkalaa qorannoo (Ingiliffa)
Qorannoo hirmaatuu barbaadduu? Fuula kana jalatti agarsiisi — $99 guyyaa 30f →
PRE-ISPY Phase I/II Oncology Platform Program
Namoota walitti qabaa jiraSadarkaa 1/2
- Mayo Clinic Comprehensive Cancer Center, Rochester
Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy
Namoota walitti qabaa jira
- Mayo Clinic, Rochester
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
Namoota walitti qabaa jiraQorannoo ilaalaa
- Mayo Clinic Rochester, Rochester
Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies
Namoota walitti qabaa jiraSadarkaa 2
- Mayo Clinic, Rochester
First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- Mayo Clinic, Rochester
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
Namoota walitti qabaa jiraSadarkaa 3
- Mayo Clinic Rochester, Rochester
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
Namoota walitti qabaa jiraSadarkaa 1
- Mayo Clinic Rochester, Rochester
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- Mayo Clinic - Rochester, Rochester
Phase 1 Study of CLR 125 in Triple Negative Breast Cancer
Namoota walitti qabaa jiraSadarkaa 1
- Mayo Clinic Rochester, Rochester
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
Namoota walitti qabaa jiraSadarkaa 2
- Mayo Clinic, Rochester
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
Namoota walitti qabaa jiraSadarkaa 1/2
- Mayo Clinic, Rochester
Qorannoo Kansaar Onnee Triple-Negative magaalota biroo keessatti
- Houston, TXQorannoo 42
- New York City, NYQorannoo 31
- Nashville, TNQorannoo 28
- Los Angeles, CAQorannoo 27
- Boston, MAQorannoo 26
- San Antonio, TXQorannoo 23
- St. Louis, MOQorannoo 21
- Arlington, VAQorannoo 20
- Atlanta, GAQorannoo 20
- Dallas, TXQorannoo 18
- Chicago, ILQorannoo 16
- Columbus, OHQorannoo 16
Qorannoo biroo Rochester keessatti
- Saree OljooQorannoo 42
- Kansara Qara'a Non-Small CellQorannoo 37
- Kansara MetastatikiiQorannoo 31
- Saree (Gosoota Hunda)Qorannoo 30
- Kansarii OvariiQorannoo 29
- Kansarii ColorectalQorannoo 29
- Myeloma Baay’eeQorannoo 24
- Cufama OnneeQorannoo 22
- Kansarii ProstateQorannoo 22
- Kansarii PancreasQorannoo 22
- Kansa EndometiriyaaliiQorannoo 20
- Dhibee QaraQorannoo 20
Kanneen ClinicalTrials.gov irraa argaman, daataa 06-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.